CCRA AGM Roundup 2017

Housed within the dramatic and suitably clinical-feeling Miller Insurance offices near Aldgate in London, a gathering of great clinical minds occurred for the CCRA AGM. Professor Atholl Johnston, President, opened up the day with introductions before we launched into 5 presentations back-to-back. Firstly we heard from Andy Catton, a Partner at Miller Insurance, on specialist

Continue Reading

Cellectis and Weill Cornell Collaborate to Develop New Leukaemia Immunotherapies

Cellectis, a French biopharmaceutical firm, has entered into a translational research collaboration with Weill Cornell Medical College situated in the US. The alliance will aim to fast-track development of a targeted immunotherapy for patients with acute myelogenous leukaemia (AML). The partnership will be combining Cellectis’ work in the development and manufacture of gene edited CAR

Continue Reading

J&J and GlaxoSmithKline’s Sirukumab Phase III Trials Begin

GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody.  The

Continue Reading